SAVVY Vaginal Gel
C31G Vaginal Gel
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Pericoital
- Development Stage: Phase III
- Developer(s)/researcher(s): Adamis Pharmaceuticals/BioSyn, FHI 360
Details
- API: Myristamine Oxide, Cetyl Betaine
- Target: Undetermined
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Inhibition of Sperm Capacitation
- Regimen: On Demand
- MPT: Potential MPT
Product Status
Adamis (now DMK Pharmaceuticals) has restructured and is going through bankruptcy. Their work is now focused on their sole FDA approved product, an overdose treatment.
History
Significant progress in the early 2000s, but stalled at Ph II/III. SAVVY was a possible MPT candidate, but was found to not significantly protect against HIV transmission.